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Hydryllin is one of a considerable number of antihistamine compounds which
have become available in recent years. While experimental studies in animals
are useful in determining whether or not a particular compound has antihis-
taminic effects, such experiments can serve as only a very rough screen in predict-
ing the clinical usefulness of these drugs in man. Moreover, determination of
the "anti-allergic" effects of any compound in man is difficult at best. The
functional physiology of the human animal is extremely variable in many re-
spects, and particularly so in the group of diseases regarded as allergic.
The use of histamine electrophoresis as a method of determining the relative
antihistaminic effects of various compounds in man has proven useful (1) and
Hydryllin has shown a satisfactory action as tested by this method. Hydryllin
is a mixture of diphenhydramine and aminophyllin. The antihistamine effects
of diphenhydramine hydrochloridet are well established; however, annoying
side reactions have been noticed following the administration of therapeutically
effective doses in man. Feinberg regards these side reactions as closely related
to the antihistaminic effect, and a result of depression of higher centers (2).
Aminophyllin has long been known to have some antihistamine activity (3).
Goodman and Gilman state that it produces smooth muscle relaxation, and that
it is an effective central nervous system stimulant, acting on the cortex, medulla
and spinal cord (4). Hydryllin, employing a combination of aminophyllin and
diphenhydramine, is designed to augment the antihistamine effect of the latter,
and to decrease the incidence of side reactions produced by diphenhydramine
administered alone.
The present study records the effect of Hydryllin on the course of various
cutaneous diseases in 154 patients. Most of the patients were suffering from
diseases which are generally considered to have an allergic component. The
patients treated were from two to seventy-nine years of age, and there were 64
males and 90 females.
The initial dose of Hydryllin2 administered, except in the case of small children,
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1 Name officially adopted by the Council on Pharmacy and Chemistry of the American
Medical Association for beta-dirnethyl-aminoethyl-benzhydryl ether hydrochloride or
Benadryl hydrochloride.
1 A single tablet of Hydryllin contains 25 mgm. of diphenhydramine and 100 mgm. of
aminophyllin.
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DIAGNOSIS TOTAL NUMBERCASES
IMPROVEMENT
None
-_________
Equivocal* Good Excellent
Atopic dermatitis 23 12 7 4 0
Contact dermatitis 22 10 4 8 0
Acute urticaria 11 1 0 3 7
Chronic urticaria 16 2 2 8 4
Papular utricaria 2 1 1 0 0
Eczematous dermatitis 22 17 2 3 0
Localized neurodermatitis 6 5 1 0 0
Dermatitis medicamentosa
a. Penicillin 9 1 1 5 2
b. Sulfonamides 2 1 0 0 1
c.Gold 1 1 0 0 0
d.Niacin 1 1 0 0 0
Exfoliative dermatitis 4 1 1 2 0
Generalized pruritus, cause undeter-
mined 3 1 1 1 0
Pruritus ani 2 1 1 0 0
Pruritus vulvae 3 2 1 0 0
Dermatitis herpetiformis 6 4 0 2 0
Neurotic excoriation 2 2 0 0 0
Lichen planus 1 1 0 0 0
Seborrheic dermatitis 1 1 0 0 0
Psoriasis 1 1 0 0 0
Erythema multiforrne 2 2 0 0 0
Stasis dermatitis 2 0 1 1 0
Infectious eczematoid dermatitis. . . . 5 2 1 2 0
Angioneurotie edema 7 1 2 4 0
Totals 154 71 26 43 14
456 THE JOURNAL OF INVE3TIGATIVE DERMPiTOLOGY
was one tablet three or four times daily. If no improvement was noted, and no
side effects produced, this dose was increased to two tablets every four to six
hours.
The results obtained are recorded in Table 1.
TABLE 1
Clinical result8 obtained from Hydryllin in a variety of dermatoses
* "Excellent" results indicate complete or nearly complete relief of both signs and
symptoms. "Moderate" results indicate definite but not complete relief. Patients with
"equivocal" results apparently obtained a little improvement, but were not subjected to
control studies with placebos.
In diseases such as atopic dermatitis, urticaria and other itching dermatoses
the effectiveness of suggestion may be high, and the evaluation of new therapeutic
measures must be controlled by comparison with blank or placebo medication.
This well-known fact was again beautifully illustrated in the recent report of
Spencer and Brown (5).
In the present study the relative effectiveness of ilydryllin was compared to
that of placebo tablets in 57 patients. In all these patients, some benefit had
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apparently resulted from the administration of Hydryllin. A change to placebo
tablets was made without the patient's knowledge. Patients who experienced
subjective and/or objective relapse during placebo therapy were again given
Hydryllin, and if improvement followed this readministration, Hydryllin was
considered to be responsible for the beneficial effect. In those patients who
obtained as much or more relief from placebos as from Hydryllin, no improvement
was attributed to Hydryllin. It is probable, however, that this group includes
TABLE 2
Atropic dermatitis
Contact dermatitis
Acute urticaria
Chronic urticaria
Papular urticaria
Eczematous dermatitis
Localized neurodermatitis
Dermatitis medicamentosa (penicillin)...
Exfoliative dermatitis
Generalized pruritus, cause undeter-
mined
Dermatitis herpetiformis
Seborrheic dermatitis
Psoriasis
Erythema multiforme
Angioneurotic edema
SVMBER 01' PATIENTS NUMBER 01' PATIENTS
RELAPSING ON UNCHANGED BY
PLACEBO THERAPY PLACEBO THERAPY
4 5
4 8
1 4
6 2
o i
3 1
o 1
o 2
2 0
* The placebo tablets contained glucose, and were indistinguishable from Hydryllin
tablets.
f All these patients had experienced some improvement following administration of
Hydryllin.
Reactions: Thirty of the 154 patients treated developed mild to moderately severe
reactions from Hydryllin. These are recorded in Table 3.
some patients whose disease was undergoing involution, and that some benefit
may actually have been obtained from Ilydryllin initially. The results are out-
lined in Table 2.
Although single side effects were noted in some patients, they were more fre-
quently multiple. In the 30 patients showing reactions (19.5%) discontinuance
of Hydryllin therapy was considered advisable in 23 (14.9%). The other seven
patients were able to continue Hydryllin therapy without difficulty, particularly
if the drug was administered after meals.
One patient who developed a dermatitis after administration of Hydryllin
was subsequently shown to be sensitive to aminophyllin. This patient initiaUy
DIAGNOSIS
Results obtained with placebo tablets* in a group of patients originally treated with Hydryllin
TOTAL NUMBER OR
PATIENTSt
9
12
5
8
1
4
1
2
2
2
3
1
1
1
5
1
2
0
0
0
4
1
1
1
1
1
1
Totals 57 27 30
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had a m.orbilliform dermatitis of his trunk because of sensitivity to penicillin.
Hydryllin (1 tablet q.i.d.) was administered, and 48 hours later the patient de-
veloped angioneurotic edema of the upper lip and fingers, and large urticarial
lesions on the trunk and upper extremities. Hydryllin was discontinued, and
tripelennamine hydrochloride' (50 mgm. q.i.d.) was given. Seventy-two hours
later the original dermatitis medicamentosa as well as the urticaria and angio-
neurotic edema disappeared. Tripelennamine hydrochloride was then discon-
tinued and diphenhydramine hydrochloride (25 mgm. q.i.d.) was administered.
No cutaneous lesions developed after three days of diphenhydramine hydro-
TABLE 3
Order of frequency of side effects encountered in 30 of 154 patients treated with Hydryllin
SIDE REACTIONS TOTAL INCIDENCE
• . (Severe.... 7) 11Dizziness
iMild 4f
(Severe.... 8) 10INausea Mild 2f
(Severe.... 4) 8
Drowsiness .Mild 4f
(Severe.... 51 8
Vomiting <LMild 3f
(Severe.... 8Weakness Mild 2J
Abdominal pain 5
Ataxia 4
Headache 3
Anorexia a
Tremor 2
Diarrhea 2
Diplopia 2
Tachycardia 2
Dermatitis 1
Muscular aching 1
Insomnia 1
Nervousness 1
Dryness of mouth 1
chloride therapy, and aminophyllin (100 mgm. q.i.d.) was then substituted.
Within 24 hours, the urticarial eruption reappeared. This reaction promptly
disappeared following discontinuance of aminophyllin administration. It is
believed that this sequence of events furnishes evidence of this patient's sensi-
tivity to the aminophyllin component of Hydryllin.
DISCUSSION
The effect of drugs designed to influence lesions on the skin may be determined
'Official name adopted by the Council in Pharmacy and Chemistry of the American
Medical Association for pyridil-N'benzyl-N-dimethyethylenq-diamine or Pyribenzamine
hydrochloride.
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somewhat more easily than with organs which are not visible. Nevertheless,
erroneous conclusions as to the effectiveness of a particular compound may result
(1) if control studies are not carried out, (2) if the great variability of the course
of allergic dermatoses in man is not constantly kept in mind, and (3) if the possible
psychotherapeutic effect of any drug, particularly a new and experimental one,
is not recognized. Failure to recognize these factors, among others, may produce
confusion in the clinical evaluation of antihistamine compounds. Almost all
the reported clinical studies relating to the effects of these compounds on allergic
derrn.atoses have been carried out without controls.
Fifty-seven patients who obtained subjective and/or objective relief from
Hydryllin were given placebo tablets. Thirty of them subsequently demon-
strated no objective or symptomatic change, but 27 patients developed a clinical
relapse. The non-relapsing groups were not considered to have obtained relief
attributable to Hydryllin, and were placed in the "none" improvement group
(Table 1). Those patients who relapsed (on placebos) and who again improved
when Hydryllin was readministered, were classified as having a "good" or "ex-
cellent" result (Table 1).
The use of placebos proved to be most helpful in evaluating the efficacy of an
antihistamine drug in chronic cutaneous diseases such as atopic dermatitis,
chronic urticaria, eczematous dermatitis, localized neurodermatitis, exfoliative
dermatitis, local or general pruritus of varying etiology, dermatitis herpetiformis,
erythema multiforme and angioneurotic edema. Our experience with the 23
patients with atopic dermatitis clearly demonstrates the importance of controls.
Nine patients initially seemed to benefit from Hydryllin. However, when these
same 9 patients received placebo tablets, 7 to 10 days later, four had clinical
relapses, whereas five patients apparently obtained as much relief from the placebos
as Hydryllin. If placebos had not been administered, all 9 patients would have
been regarded as benefited by Hydryllin, and the analysis of the effectiveness of
this drug in atopic dermatitis would have been inaccurate.
Placebo therapy in acute cutaneous diseases such as urticaria, contact derma-
titis, and dermatitis medicamentosa was not as informative as in the chronic
diseases listed above. Hydryllin was apparently beneficial to many patients
with these three diseases despite the fact they did not all relapse on placebos.
Ten of 11 acute urticarias were recorded in the "good" or "excellent" improve-
ment categories (Table 1), despite the fact that only one of these patients re-
lapsed on placebo while 4 did not. The majority of the non-relapsing group of
acute urticarias were considered to be helped by Hydryllin because of the marked
clinical relief obtained.
Hydryllin seemed to be most efficacious in the treatment of acute and chronic
urticaria, angioneurotic edema and penicillin dermatitis medicamentosa. Some
patients with contact dermatitis and atopic dermatitis may be aided. Larger
series of patients must be accurately evaluated before any final conclusion is
reached as to the effect on exfoliative dermatitis, and dermatitis herpetiformis.4
Very little or no improvement was obtained in patients with eczematous contact
Two dermatitis herpetiformis patients had subjective relapses on placebos, and each
then continued to develop new cutaneous lesions while taking Hydryllin.
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type dermatitis, localized neurodermatitis, pruritus au and vulvae, generalized
or localized pruritus of varying etiology, neurotic excoriations, lichen planus,
seborrheic dermatitis, psoriasis and erythema multiforme.
The incidence of side effects from diphenhydramine hydrochloride varies from
30—67%, 6, 7, 8. Tripelennamine hydrochloride produces side reactions in
17—40% of patients, 9, 10, 11. In this series of patients treated with Hydryllin,
the total incidence of side effects was 19.5%, and 14.9% of the patients had re-
actions of sufficient intensity to necessitate discontinuing Hydryllin. The side
reactions noted in the Hydryllin series were similar to those reported from
diphenhydramine hydrochloride and triplennamine hydrochloride.
SUMMARY
1. Hydryllin was administered to 154 patients with a variety of cutaneous
diseases. It seemed to be most efficacious in the treatment of acute and chronic
urticaria, angioneurotic edema, and penicillin dermatitis medicamentosa. Some
patients with contact dermatitis and atopic dermatitis seemed to obtain some
relief from Hydryllin. No improvement was noted in most of the patients with
eczematous dermatitis, pruritus ani and vulvae, localized neurodermatitis,
neurotic excoriations, lichen planus, psoriasis, and erythema multiforme.
2. Control placebo therapy in fifty-seven patients assisted the evaluation of
the effectiveness of Hydryllin by eliminating psychogenic factors.
3. Hydryllin produced side reactions in a total of 19.5% of 154 patients treated.
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